Intermittent androgen suppression for prostate cancer (Q37788956)

23 August 2017

title

Intermittent androgen suppression for prostate cancer (English)

1 reference

23 August 2017

1 reference

Nicholas C. Buchan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20842189

13 July 2024

S. Larry Goldenberg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20842189

13 July 2024

language of work or name

English

0 references

publication date

14 September 2010

1 reference

full work available at URL

23 August 2017

http://www.nature.com/articles/nrurol.2010.141.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

http://www.nature.com/articles/nrurol.2010.141

13 July 2024

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

13 July 2024

published in

Nature Reviews Urology

1 reference

23 August 2017

volume

7

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

552-560

1 reference

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Management of complications of androgen deprivation therapy in the older man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Experimental treatment of prostatic cancer by intermittent hormonal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent endocrine therapy for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent androgen suppression in patients with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent Androgen Deprivation for Patients With Recurrent/Metastatic Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Cellular changes in prostate cancer cells induced by intermittent androgen suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

EAU guidelines on prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.141

Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up

31 March 2020

1 reference

12 December 2020

Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies

1 reference

12 December 2020

Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma

1 reference

12 December 2020

VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer. Veterans Administration Cooperative Urological Research Group.

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Hormonal control of growth and progression in tumors of Nb rats and a theory of action

1 reference

12 December 2020

Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy

1 reference

12 December 2020

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors

1 reference

12 December 2020

Intermittent versus continuous androgen suppression for prostatic cancer

1 reference

12 December 2020

Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).

1 reference

12 December 2020

Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma

1 reference

12 December 2020

1

1

293

C Huggins

1941

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

13 July 2024

7

37

82

RL Noble

1977

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

13 July 2024

8

50

2275

N Bruchovsky

1990

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

13 July 2024

10

47

5967

P Russo

1987

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

13 July 2024

12

52

1598

ME Gleave

1992

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.141

13 July 2024

Identifiers

1 reference

23 August 2017

1 reference